carbetocin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 13 Diseases   25 Trials   25 Trials   318 News 


«123456»
  • ||||||||||  carbetocin / Generic mfg.
    Clinical, Retrospective data, Journal:  Effect of Carbetocin on Postpartum Hemorrhage after Vaginal Delivery: A Meta-Analysis. (Pubmed Central) -  Jul 1, 2022   
    There was no heterogeneity among studies (χ = 3.06, P = 0.55, I = 0%) and no significant publication bias (P > 0.05). Carbetocin is superior to oxytocin in preventing PPH among women with vaginal delivery and can be widely used in clinical practice.
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  EMGPHP: EMG for Uterotonic Efficiency Estimation (clinicaltrials.gov) -  Jun 27, 2022   
    P=N/A,  N=60, Completed, 
    Carbetocin is superior to oxytocin in preventing PPH among women with vaginal delivery and can be widely used in clinical practice. Recruiting --> Completed | Trial completion date: Dec 2022 --> Jan 2022 | Trial primary completion date: Dec 2022 --> Jan 2022
  • ||||||||||  carbetocin / Generic mfg.
    Journal:  Optimal uterotonic management. (Pubmed Central) -  Jun 8, 2022   
    Carbetocin is a chemical modification of oxytocin with a longer half-time, and therefore one bolus of carbetocin is usually sufficient. Its heat stability makes it an ideal candidate in resource-restricted settings.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Preclinical, Journal:  Oxytocin modulation in the medial prefrontal cortex of pair-exposed rats during fear conditioning. (Pubmed Central) -  May 31, 2022   
    Our findings suggest that reduction of fear-related behavior induced by acute pair-exposure is mediated by oxytocin receptors in the PL mPFC. Pair exposure with conspecifics during fear-inducing situations helps coping with fear by significantly increasing the role of oxytocin in the PL mPFC.
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  CMT2014/2: Carbetocin Myocardium Trial 2014 Part 2 (clinicaltrials.gov) -  May 20, 2022   
    P4,  N=240, Completed, 
    This finding could be relevant to the anesthesiologist caring for parturients in whom a slight increase in maternal heart rate is clinically undesirable. Recruiting --> Completed | Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Mar 2022
  • ||||||||||  Pabal (carbetocin) / Ferring
    Journal:  Uterine atony. (Pubmed Central) -  May 6, 2022   
    Recruiting --> Completed | Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Mar 2022 There is a critical, unmet need for contemporary, controlled studies to address the increasing threat of atonic PPH.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Review, Journal:  Implementing Heat-Stable Carbetocin for Postpartum Haemorrhage Prevention in Low-Resource Settings: A Rapid Scoping Review. (Pubmed Central) -  Apr 19, 2022   
    There is a lack of evidence on the feasibility (beyond cost-effectiveness), acceptability, and health system considerations related to implementing HSC in resource-constrained and lower-level maternity facilities. Further implementation research is needed to help decision-makers and practitioners offer an HSC-inclusive intervention package to prevent excessive bleeding among pregnant women living in settings where oxytocin is not available or of dubious quality.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Journal:  Carbetocin versus oxytocin following vaginal and Cesarean delivery: a before-after study. (Pubmed Central) -  Apr 8, 2022   
    Further implementation research is needed to help decision-makers and practitioners offer an HSC-inclusive intervention package to prevent excessive bleeding among pregnant women living in settings where oxytocin is not available or of dubious quality. There was no difference in the use of additional uterotonics when carbetocin or oxytocin were used in a cohort of women undergoing vaginal deliveries and both elective and emergency Cesarean deliveries.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Clinical, Journal:  Cost Implications of Using Carbetocin Injection to Prevent Postpartum Hemorrhage in a Greater Toronto Area Hospital. (Pubmed Central) -  Mar 25, 2022   
    The use of room temperature stable carbetocin as a first-line prophylactic agent for PPH prevention meets WHO recommendations regarding uterotonics for PPH in a GTA hospital. The model from this study can be used to determine the financial impact of switching from oxytocin to carbetocin in other jurisdictions while diversifying a hospital's pool of PPH prophylactic agents.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Preclinical, Journal:  Non-invasive method of obtaining milk from mice using carbetocin, a synthetic analogue of oxytocin. (Pubmed Central) -  Mar 18, 2022   
    The model from this study can be used to determine the financial impact of switching from oxytocin to carbetocin in other jurisdictions while diversifying a hospital's pool of PPH prophylactic agents. The use of carbetocin has proven to be an effective non-invasive method to obtain up to 0.89 g of milk from one mouse in 20 min.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Preclinical, Journal:  Oxytocin-induced anxiogenic behavior in juvenile male rats. (Pubmed Central) -  Jan 26, 2022   
    Moreover, increased anxiety-like behaviors and corticosterone levels were observed in the OT analog carbetocin-injected rats...Collectively, these results provide evidence that acute OT exposure could induce anxiogenic behavior with corticosterone augmentation, contributing to the attenuation of nicotine preference. This suggests that both aspects of OT, as well as their benefits and drawbacks, should be considered.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Review, Journal:  Refractory uterine atony: still a problem after all these years. (Pubmed Central) -  Dec 16, 2021   
    Carbetocin, available in many countries, is a synthetic oxytocin analog with a longer duration than oxytocin that allows bolus administration without an infusion...Currently, the choice of second-line agent should be based on their adverse effect profile and patient comorbidities. Surgical and radiologic management of uterine atony includes uterine tamponade using balloon catheters and compression sutures, and percutaneous transcatheter arterial embolization.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Journal:  A survey of anaesthetists on uterotonic usage practices for elective caesarean section in Australia and New Zealand. (Pubmed Central) -  Dec 16, 2021   
    Thirty-eight per cent of anaesthetists routinely administered Royal College of Obstetricians and Gynaecologists guideline-recommended 5 IU, whereas 38% favoured low dose (<5 IU), 10% high dose (≥10 IU) oxytocin and 13% carbetocin (100 µg)...This variation may be due to a lack of strong evidence to guide practice. This emphasises the need for high quality trials in this clinically important area.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Clinical, Journal:  Effect of heat stable carbetocin vs oxytocin for preventing postpartum haemorrhage on post delivery hemoglobin-a randomized controlled trial. (Pubmed Central) -  Nov 17, 2021   
    From the regression coefficients it can be derived that post-delivery hemoglobin, adjusted for pre-delivery hemoglobin, decreases on average 0.12 g/dL for each dL of blood lost, for the two treatments combined. The present ancillary study showed that intramuscular administration of 100 µg of heat stable carbetocin can result in a slightly lower post-delivery hemoglobin, slightly higher drop and higher percentage of women having a drop of 2 g/dL or larger, compared to 10 IU of oxytocin.
  • ||||||||||  Pabal (carbetocin) / Ferring
    Preclinical, Journal:  Targeting the oxytocin system to ameliorate early life depressive-like behaviors in maternally-separated rats. (Pubmed Central) -  Oct 15, 2021   
    CBT and ESCIT manage depressive-like behavior by positively affecting serotonergic and oxytocinergic systems. Targeting OXT system -using CBT- ameliorated depressive like behaviors induced by maternal separation most probably via enhancing OXT plasma levels, attenuating hormonal ACTH and restoring the expression of hippocampal oxytocin and serotonin mechanisms.
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion, Trial completion date:  Impact of Carbetocin Administration on Heart Rate When Given as an Infusion Versus as a Bolus. (clinicaltrials.gov) -  Oct 4, 2021   
    P4,  N=70, Completed, 
    Targeting OXT system -using CBT- ameliorated depressive like behaviors induced by maternal separation most probably via enhancing OXT plasma levels, attenuating hormonal ACTH and restoring the expression of hippocampal oxytocin and serotonin mechanisms. Recruiting --> Completed | Trial completion date: Nov 2019 --> Jan 2021
  • ||||||||||  carbetocin / Generic mfg.
    Enrollment open, Head-to-Head:  Oxytocin vs Carbetocin at Cesarean Delivery in Women With Morbid Obesity (clinicaltrials.gov) -  Sep 26, 2021   
    P=N/A,  N=48, Recruiting, 
    Recruiting --> Completed | N=300 --> 135 | Trial primary completion date: Mar 2021 --> Jun 2021 Not yet recruiting --> Recruiting
  • ||||||||||  carbetocin / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy. (clinicaltrials.gov) -  Sep 21, 2021   
    P=N/A,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Pabal (carbetocin) / Ferring
    Preclinical, Journal:  Application of chemometric modelling to UV-Vis spectroscopy: development of simultaneous API and critical excipient assay in a liquid solution continuous flow. (Pubmed Central) -  Jun 22, 2021   
    By applying Chemometric modelling to UV-Vis spectroscopy, a single Multi-Variate Data Analysis predictive model, for in-line monitoring of two component concentrations in solution formulation, was developed. The purpose of this article is to summarize the experimental development work performed for the UV-Vis analytical method and calibration modelling to determine the content of active pharmaceutical ingredient Carbetocin and the content of one critical excipient (l-methionine) in PABAL® solution for injection 100 µg/mL.
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion:  CaRDIO: Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study (clinicaltrials.gov) -  May 14, 2021   
    P4,  N=50, Completed, 
    The purpose of this article is to summarize the experimental development work performed for the UV-Vis analytical method and calibration modelling to determine the content of active pharmaceutical ingredient Carbetocin and the content of one critical excipient (l-methionine) in PABAL® solution for injection 100 µg/mL. Recruiting --> Completed
  • ||||||||||  carbetocin / Generic mfg.
    Trial primary completion date:  CMT2014/2: Carbetocin Myocardium Trial 2014 Part 2 (clinicaltrials.gov) -  Mar 10, 2021   
    P4,  N=240, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Jan 2021 --> Aug 2021
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion, Head-to-Head:  Carbetocin vs. Oxytocin at Elective Cesarean Section (clinicaltrials.gov) -  Mar 3, 2021   
    P=N/A,  N=278, Completed, 
    Trial primary completion date: Jan 2021 --> Aug 2021 Recruiting --> Completed
  • ||||||||||  carbetocin / Generic mfg.
    New trial:  Uterotonics for Severe Preeclampsia (clinicaltrials.gov) -  Feb 15, 2021   
    P=N/A,  N=124, Completed, 
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion date, Trial primary completion date:  Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S. (clinicaltrials.gov) -  Feb 2, 2021   
    P4,  N=200, Recruiting, 
    Recruiting --> Completed Trial completion date: Apr 2019 --> Apr 2021 | Trial primary completion date: Apr 2019 --> Apr 2021
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion date, Trial primary completion date:  Carbetocin Versus Misoprostol in High Risk Patients for Postpartum Hemorrhage After C.S. (clinicaltrials.gov) -  Feb 2, 2021   
    P4,  N=200, Recruiting, 
    Trial completion date: Apr 2019 --> Apr 2021 | Trial primary completion date: Apr 2019 --> Apr 2021 Trial completion date: Aug 2019 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2021
  • ||||||||||  carbetocin / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy. (clinicaltrials.gov) -  Nov 13, 2020   
    P=N/A,  N=30, Not yet recruiting, 
    Trial completion date: Aug 2019 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2021 Trial completion date: Dec 2020 --> Dec 2021 | Initiation date: Jul 2020 --> Jan 2021 | Trial primary completion date: Dec 2020 --> Dec 2021